What Happened?

Shares of biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price target. 

The analyst firm pointed to a changing outlook for the company's potential treatment for IgA nephropathy (IgAN), a type of kidney disease. This positive view was based on several factors, including favorable pricing by a competitor and Vertex's plans to use a priority review voucher, which can speed up the drug approval process. The upgrade also reflected growing optimism around the upcoming results for its drug candidate, povetacicept, expected in early 2026.

After the initial pop the shares cooled down to $466.75, up 4% from previous close.

Is now the time to buy Vertex Pharmaceuticals? Access our full analysis report here.

What Is The Market Telling Us

Vertex Pharmaceuticals’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 5 months ago when the stock dropped 17.4% on the news that the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. 

The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop the development of VX-993 as a standalone treatment for acute pain. This setback in the company's drug pipeline overshadowed its recently reported strong second-quarter financial results. The news also compounded concerns after the company revealed that expanding the approval for another pain medicine, Journavx, also faced regulatory hurdles.

Vertex Pharmaceuticals is up 3.2% since the beginning of the year, but at $466.75 per share, it is still trading 9.1% below its 52-week high of $513.76 from March 2025. Investors who bought $1,000 worth of Vertex Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $2,059.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.